Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nephropathy
Biotech
Vertex races to FDA after phase 3 kidney disease data impress
The phase 3 win for povetacicept met analyst expectations and fired the starting gun on a race to the FDA that could result in a November approval.
Nick Paul Taylor
Mar 10, 2026 6:20am
Climb Bio ascends from Eliem legacy, buying IgA antibody for $9M
Jan 9, 2025 10:07am
Analysts hail Vera's kidney drug as potential 'functional cure'
Oct 28, 2024 9:27am
Vertex pays $4.9 billion to hike Alpine’s immunology trail
Apr 10, 2024 5:30pm
Novartis' $3.2B Chinook bet takes flight as phase 3 hits goal
Oct 30, 2023 8:16am
Omeros stops kidney disease phase 3 after interim review fail
Oct 16, 2023 8:45am
